ACE2 Activation Promotes Antithrombotic Activity
Explore this paper's citation graph
Summary
Results suggest that ACE2 could be a novel target for the treatment of thrombogenic diseases and attenuates thrombus formation and reduces platelet attachment to vessels.
- Type
- article
- Published
- 2009-04-01
- Cited by
- 128
- References
- 28
- Access
- Open access
- OpenAlex
- https://openalex.org/W17887271
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:11288103
Keywords
Thrombus, Platelet, Platelet activation, Thrombosis, Medicine
References
- Angiotensin II Increases Plasminogen Activator Inhibitor-1 and Tissue Factor mRNA Expression without Changing that of Tissue Type Plasminogen Activator or Tissue Factor Pathway Inhibitor in Cultured Rat Aortic Endothelial Cells
- Recent advances in the angiotensin‐converting enzyme 2–angiotensin(1–7)–Mas axis
- Angiotensin II Increases Plasminogen Activator Inhibitor Type 1 and Tissue‐Type Plasminogen Activator Messenger RNA in Cultured Rat Aortic Smooth Muscle Cells
- Murine model of ferric chloride‐induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor
- A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9
- Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas
- Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension.
- Late ventricular remodeling in non-reperfused acute myocardial infarction in humans is predicted by angiotensin II type 1 receptor density on blood platelets.
- Angiotensin-converting enzyme 2 is an essential regulator of heart function
- The antithrombotic effect of angiotensin-(1—7) closely resembles that of losartan
- Angiotensin II can induce and potentiate shape change in human platelets: effect of losartan
- Platelets and Cardiovascular Disease
- Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis.
- Genomic and proteomic approaches for targeting of angiotensin-converting enzyme2 for cardiovascular diseases
- Cloning and characterization of a secreted form of angiotensin-converting enzyme 2.
- Multimodal optical imaging of microvessel network convective oxygen transport dynamics.
- The Antithrombotic Effect of Angiotensin-(1-7) Involves Mas-Mediated NO Release from Platelets
- Hypertension, platelets, and the endothelium: the "thrombotic paradox" of hypertension (or "Birmingham paradox") revisited.
- Nitric oxide insufficiency, platelet activation, and arterial thrombosis.
- Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis.
Cited by
- Chronic Activation of Endogenous Angiotensin-Converting Enzyme 2 Protects Diabetic Rats from Cardiovascular Autonomic Dysfunction
- Angiotensin II-related hypertension and eye diseases.
- Diminazene protects corpus cavernosum against hypercholesterolemia-induced injury.
- New Cardiovascular and Pulmonary Therapeutic Strategies Based on the Angiotensin-Converting Enzyme 2/Angiotensin-(1–7)/Mas Receptor Axis
- Angiotensin-converting enzyme 2 is subject to post-transcriptional regulation by miR-421.
- The Angiotensin-Converting Enzyme 2/Angiotensin-(1–7)/Mas receptor axis: A potential target for treating thrombotic diseases
- Angiotensin-Converting Enzyme 2: The First Decade
- Osteopontin and integrin are involved in cholesterol gallstone formation
- Angiotensin 1-7 and Mas decrease thrombosis in Bdkrb2-/- mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation.
- ACE2 activation by xanthenone prevents leptin-induced increases in blood pressure and proteinuria during pregnancy in Sprague-Dawley rats.
- ACE2 and Ang-(1-7) confer protection against development of diabetic retinopathy.
- Angiotensin converting enzyme 2 and atherosclerosis.
- Role of renin-angiotensin system and oxidative status on the maternal cardiovascular regulation in spontaneously hypertensive rats.
- Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor.
- Opportunities for Targeting the Angiotensin-Converting Enzyme 2/Angiotensin-(1-7)/Mas Receptor Pathway in Hypertension
- Activation of angiotensin-converting enzyme 2 improves cardiac electrical changes in ventricular repolarization in streptozotocin-induced hyperglycaemic rats.
- Oral Administration of an Angiotensin-Converting Enzyme 2 Activator Ameliorates Diabetes-Induced Cardiac Dysfunction
- Three key proteases – angiotensin-I-converting enzyme (ACE), ACE2 and renin – within and beyond the renin-angiotensin system
- Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets
- Species-specific inhibitor sensitivity of angiotensin-converting enzyme 2 (ACE2) and its implication for ACE2 activity assays.
Related papers
- Experimental antithrombotic effect of potatoes harvested in the autumn
- Antithrombotic Therapy: Focus on the Elderly
- Novel antithrombotic therapy.
- Investigation on Antithrombotic Effects of Polydatin
- A thrombus is formed by a gradient of platelet activation and procoagulant endothelium
- A thrombus is formed by a gradient of platelet activation and procoagulant endothelium
- Progress of radionuclide imaging in platelet activation in thrombus
- New approaches for the assessment of platelet activation status in thrombus under flow condition using confocal microscopy